Rezvoglar Kwikpen Coupons & Prices

Rezvoglar KwikPen (insulin glargine-aglr) is a long-acting basal insulin used once daily to help manage blood sugar in adults and children with diabetes. It's an FDA-approved biosimilar that has also been designated interchangeable with Lantus, meaning a pharmacist can substitute it for Lantus in most states without a new prescription. If you're comparing a Rezvoglar KwikPen coupon against insurance copays or the reference brand's price, enter your ZIP above to see today's price at pharmacies near you.

What Is Rezvoglar KwikPen and How Does It Work?

Rezvoglar KwikPen is a prefilled injector pen containing insulin glargine-aglr, a long-acting (basal) insulin analog. It's biosimilar to Lantus and is FDA-designated as interchangeable, meaning clinical studies showed no meaningful difference in safety or effectiveness between the two. It's injected subcutaneously once daily, at the same time each day, into the abdomen, thigh, or upper arm, and works over roughly 24 hours to provide a steady background level of insulin between meals and overnight.

• Used to improve blood sugar control in adults and children with type 1 or type 2 diabetes
• Not intended for treating diabetic ketoacidosis
• Not for use in an insulin pump or given intravenously

Manufacturer Card vs. Rx.com Cash Coupon

Eli Lilly, the maker of Rezvoglar, offers its own savings program for eligible patients; terms, eligibility, and whether it applies to your insurance status vary, so check directly with Lilly. Manufacturer copay cards like this one are typically limited to people with commercial (private) insurance and generally can't be used with Medicare, Medicaid, or if you're uninsured. An Rx.com cash coupon works regardless of insurance status, including if you're uninsured, on Medicare, or if your card is declined at the counter.

Because Rezvoglar is an interchangeable biosimilar, it's already positioned as a lower-cost alternative to brand Lantus, and prices can vary meaningfully between pharmacies, so it's worth comparing before you fill.

How Rezvoglar Compares to Other Insulin Glargine Products

Rezvoglar is one of several insulin glargine products on the market. Lantus is the original reference product. Semglee is another insulin glargine biosimilar that has also received an interchangeable designation, so a pharmacist can substitute either Rezvoglar or Semglee for Lantus. Basaglar is a follow-on insulin glargine product that is not designated interchangeable, meaning a prescriber has to specify it by name. All of these are U-100 (100 units/mL) long-acting insulins dosed once daily; they are not interchangeable with U-300 concentrated glargine products, which are dosed differently.

Safety Information

The most common risk with any basal insulin, including Rezvoglar, is hypoglycemia (low blood sugar), which can cause shakiness, sweating, confusion, or in severe cases loss of consciousness. Never share a Rezvoglar KwikPen with another person, even if you change the needle, since sharing can spread bloodborne infections. Don't mix Rezvoglar with other insulins or dilute it, and rotate your injection site to help prevent skin changes at injection sites over time. This is general information, not medical advice — talk with your prescriber or pharmacist about your specific dosing and monitoring plan.